Abstract:Background: The survival rate of osteosarcoma therapy still lags behind overall cancer therapies due to the intrinsic or acquired drug resistance. Developing novel drug delivery systems that may overcome drug resistance would greatly facilitate osteosarcoma therapy. Methods: Poly(ethylene glycol) (PEG)-sheddable reduction-sensitive polyurethane (SS-PU-SS-PEG) was synthesized using a disulfide-containing polycaprolactone diol as the hydrophobic block and a cystamine-functionalized PEG as the hydrophilic block. SS-PU-SS-PEG micelles were then prepared to load the anti-tumor drug Doxorubicin (DOX) in order to achieve triggered intracellular drug delivery to improve the efficacy of osteosarcoma therapy. Results: When DOX was used as a model drug, the drug-loaded SS-PU-SS-PEG micelles were about 82 similar to 94 nm in diameter and exhibited good stability in phosphate buffer saline (PBS). The micelles could release about 80% DOX in a quantitative fashion within 5 hours under a reductive environment. The intracellular drug release of DOXloaded SS-PU-SS-PEG micelles increased upon incubation with Saos-2 cells in vitro. The micelles had good biocompatibility. In vitro, DOX-loaded SS-PU-SS-PEG micelles showed significant antitumor activity toward Saos-2 cells, which was close to that of free DOX. In vivo, DOX-loaded SS-PU-SS-PEG micelles exhibited better antitumor activity than free DOX. Conclusion: Findings from this study suggest that the SS-PU-SS-PEG micelles could achieve well-controlled triggered drug release in a reduction environment and could therefore improve the antitumor efficacy of osteosarcoma therapies. Translation potential of this article: In this study we developed PEG-sheddable reduction-sensitive polyurethane micelles (SS-PU-SS-PEG), which were able to achieve well-controlled triggered release of anti-tumor drug Doxorubicin (DOX) in an intracellular reduction environment. DOX-loaded SS-PU-SS-PEG micelles markedly improved the antitumor efficacy in a Saos-2 cells-bearing xenograft tumor model. Therefore, such micelles might be used as a novel drug delivery system for osteosarcoma treatment.

Improving Bioavailability of Hydrophobic Prodrugs Through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment.

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Correlation between Tear Osmolarity and Tear Meniscus

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

Reduction-responsive Polypeptide Nanomedicines Significantly Inhibit Progression of Orthotopic Osteosarcoma.

Nanosized drug delivery strategies in osteosarcoma chemotherapy

Poly(ethylene Glycol)-Sheddable Reduction-Sensitive Polyurethane Micelles for Triggered Intracellular Drug Delivery for Osteosarcoma Treatment

An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety

Difficulty in conditioning galvanic skin responses: its possible significance in clinical audiometry.

Biosynthetic and Unfolded Protein Nanocarriers for Chemotherapeutic Drugs in Oral Cancers: Improved Bioavailability and Safety of Chemotherapeutics

Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

Intracellular Co-delivery of proteins and chemotherapeutics using calcium carbonate mineralized nanoparticles for osteosarcoma therapy

A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma

Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles

Dynamic nanoassemblies derived from small-molecule homodimeric prodrugs for in situ drug activation and safe osteosarcoma treatment

Peritumoral Microgel Reservoir for Long-Term Light-Controlled Triple-Synergistic Treatment of Osteosarcoma with Single Ultra-Low Dose.

Integrated radiochemotherapy study of ZIF-8 coated with osteosarcoma-platelet hybrid membranes for the delivery of Dbait and Adriamycin

Zoledronic Acid-Loaded Hybrid Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticle: Novel Fabrication and Safety Verification